Welcome to our dedicated page for Electromed news (Ticker: ELMD), a resource for investors and traders seeking the latest updates and insights on Electromed stock.
Electromed, Inc. (NYSE MKT: ELMD) is a Minnesota-based company recognized as an innovative leader in the development, manufacture, and worldwide distribution of the SmartVest® Airway Clearance System. This patented system leverages High-Frequency Chest Wall Oscillation (HFCWO), offering a well-tolerated alternative to traditional chest physiotherapy (CPT). The system is designed to deliver effective and comfortable airway clearance treatment for patients suffering from the consequences of retained secretions.
Clinically proven, HFCWO technology helps clear the lungs of excess mucus, thereby improving lung function and reducing infections for individuals with conditions such as atelectasis, COPD, bronchiectasis, neuromuscular diseases, and cystic fibrosis. Electromed, Inc. is accredited by the Joint Commission and holds ISO 13485:2003 and ISO 9001:2008 certifications, demonstrating their commitment to quality and safety.
The SmartVest System consists of a programmable air pulse generator, a therapy garment worn over the upper body, and a connecting hose. Together, these components provide a safe, comfortable, and effective airway clearance therapy that enhances the quality of life for patients with compromised pulmonary function.
Electromed, Inc. continuously strives for excellence and compassionate service. Their products are designed with patient comfort and usability in mind, ensuring that users receive the best possible care. With a global reach, the company is dedicated to improving respiratory health for patients worldwide.
Stay updated with the latest developments, achievements, and financial performance of Electromed, Inc. by following their news and updates. The company's ongoing projects and partnerships underscore its commitment to innovation and excellence in the field of airway clearance therapy.
Electromed, a leader in airway clearance technologies, announced its fiscal Q1 2025 financial results. Net revenue rose by 19.0% to $14.7 million, with gross margin improving to 78.3%. Operating income increased to $1.9 million, and net income surged to $1.5 million, or $0.16 per diluted share. The company repurchased 262,756 shares at an average price of $17.26, totaling approximately $4.5 million. Electromed continues to invest in growth initiatives, including the expansion of its direct sales force to 53 reps and the launch of a new marketing campaign. Cash balance decreased by $2.2 million, primarily due to share repurchases, leaving $13.9 million in cash and no debt. The company achieved a working capital of $33.6 million.
Electromed (NYSE American: ELMD), a leader in airway clearance technologies, has announced it will release its fiscal 2025 first quarter financial results on November 12, 2024, after market close. Management will host a conference call at 5:00 p.m. Eastern Time to discuss the results. Investors can join via phone at (844) 826-3033 (Domestic) or (412) 317-5185 (International), or watch the webcast through the company's Investor Relations website.
Electromed (NYSE American: ELMD) has appointed Peter Horwich as Vice President, Marketing. Horwich brings over 20 years of experience in Medical Technology marketing, previously serving at Abiomed (now J&J MedTech) where he directed Global Strategic Marketing for Respiratory Therapies. His experience includes roles at Medtronic, Arizant, Entegris, and Guidant. CEO Jim Cunniff highlighted that this strategic appointment comes during a period of business growth and aims to drive therapy adoption for SmartVest Clearway to support revenue growth goals.
Electromed (NYSE American: ELMD), a leader in airway clearance technologies, has announced a new $5.0 million share repurchase authorization effective September 11, 2024. This follows the completion of their previous repurchase program in Q4 fiscal 2024. The company's board will determine the timing and amount of repurchases based on market conditions. Repurchases may be made through various means, including open market transactions and block trades.
CEO Jim Cunniff stated that this decision follows Electromed's record performance in fiscal 2024 and reflects the board's confidence in future growth. The company's strong revenue growth and profitability are generating robust free cash flow, allowing for shareholder value creation while continuing business investments. Management believes the stock is undervalued given their strong financial results.
Electromed, Inc. (NYSE American: ELMD) reported record financial results for Q4 and FY 2024. Highlights include:
- Q4 net revenues increased 9.0% to $14.8 million
- Q4 operating income up 56.3% to $2.3 million
- Q4 net income reached $1.8 million or $0.20 per diluted share
- FY 2024 net revenue grew 13.8% to $54.7 million
- FY 2024 operating income increased 64.2% to $6.6 million
- FY 2024 net income totaled $5.2 million or $0.58 per diluted share
The company attributed growth to investments in commercial infrastructure and market development initiatives. As of June 30, 2024, Electromed had $16.1 million in cash, $23.3 million in accounts receivable, and no debt.
Electromed, Inc. (NYSE American: ELMD), a leader in innovative airway clearance technologies, has announced its upcoming financial results release and conference call for the fourth quarter of fiscal 2024. The company will issue its financial results press release on August 27, 2024, after the stock market closes. Management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results.
Interested parties can participate in the call by dialing (877) 407-0789 (Domestic) or (201) 689-8562 (International). A live webcast will be accessible on Electromed's website in the Investor Relations section. For those unable to listen live, a replay will be available by phone and online.
Electromed, a leader in innovative airway clearance technologies, announced its participation in the Canaccord Genuity 44th Annual Global Growth Conference in Boston from August 13-15, 2024. Jim Cunniff, President and CEO, and Brad Nagel, CFO, will present on Wednesday, August 14, 2024, at 2:30 p.m. Eastern Time.
The presentation will be available via live and archived webcast on Electromed's website under Events & Presentations. Additionally, Electromed has published an updated investor presentation deck for review, accessible on their website and the SEC website.
Electromed, known for its innovative airway clearance technologies, announced that its top executives, President and CEO Jim Cunniff and CFO Brad Nagel, will attend the 2024 Sidoti June Small-Cap Virtual Conference. This event is scheduled for June 12-13, 2024. Electromed will present at 1:45 p.m. ET on June 12, 2024. A live and archived webcast of their presentation will be accessible via the Electromed website.
Electromed, Inc. achieves record revenue in the third quarter of fiscal year 2024, with a 15% increase to $13.9 million compared to the prior year. Operating income rises by 54%, net income reaches $1.49 million, and cash balance grows to $11.7 million. The company's direct homecare business revenue increases by 12%, showing strong growth and operational efficiency. The gross profit margin remains stable at 75%. Electromed continues to focus on driving adoption of its products, enhancing shareholder value, and sustaining operating leverage for profitability.
FAQ
What is the current stock price of Electromed (ELMD)?
What is the market cap of Electromed (ELMD)?
What does Electromed, Inc. do?
What conditions does the SmartVest® Airway Clearance System help with?
What is High-Frequency Chest Wall Oscillation (HFCWO)?
Is Electromed, Inc. certified?
What are the components of the SmartVest® System?
Where is Electromed, Inc. based?
How does the SmartVest® improve patient health?
Where can I find the latest news about Electromed, Inc.?
Does Electromed, Inc. operate worldwide?
What is the goal of Electromed, Inc.?
